Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.

about

Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.

Item

http://www.wikidata.org/entity/Q38764223

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical impact of pretranspla ...... chronic myelogenous leukemia.

@en

type

Item

label

Clinical impact of pretranspla ...... chronic myelogenous leukemia.

@en

prefLabel

Clinical impact of pretranspla ...... chronic myelogenous leukemia.

@en

P1476

Clinical impact of pretranspla ...... chronic myelogenous leukemia.

@en

P2093

Arinobu Tojo

http://www.w3.org/2001/XMLSchema#string

Fumitaka Nagamura

http://www.w3.org/2001/XMLSchema#string

Heiwa Kanamori

http://www.w3.org/2001/XMLSchema#string

Hirohisa Nakamae

http://www.w3.org/2001/XMLSchema#string

Hironori Ueno

http://www.w3.org/2001/XMLSchema#string

Hisako Hashimoto

http://www.w3.org/2001/XMLSchema#string

Kazuteru Ohashi

http://www.w3.org/2001/XMLSchema#string

Makoto Onizuka

http://www.w3.org/2001/XMLSchema#string

Minoko Takanashi

http://www.w3.org/2001/XMLSchema#string

Naoyuki Uchida

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the intensity of conditioning regimens: working definitions

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S.

Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data).

Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

P304

902-908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24793

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Takehiko Mori

Takeshi Kondo

Mineo Kurokawa

P577

2017-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28543934

http://www.w3.org/2001/XMLSchema#string